COYA 302 combination therapy tames brain inflammation in mice
Subcutaneous, or under-the-skin, injections of COYA 302, a combination therapy in development by Coya Therapeutics, were found to reduce…
Articles by Margarida Maia, PhD
Study review highlights limits of levodopa effectiveness
Note: This story was updated Sept. 16, 2024, to correct that A-dopamine is a form of dopamine. Levodopa, a…
StrivePD’s new AI app feature may help manage Parkinson’s care
Rune Labs has launched StrivePD-AI, a new feature in its StrivePD app that uses generative artificial intelligence (GenAI) to…
APDA awards $2.6M to support Parkinson’s research projects
The American Parkinson Disease Association (APDA) has awarded a total of $2.6 million for the 2024-2025 funding year, to…
FDA letter supports use of new alpha-synuclein assay in trials
The U.S. Food and Drug Administration (FDA) is encouraging scientists and drug developers to use an alpha-synuclein seed amplification assay…
Mechanism to weaken unused brain connections affected in Parkinson’s
The brain weakens unused neural connections in the striatum, a region involved in motor control and decision-making, through a nitric…
Acute kidney injury raises risk of dementia, including in Parkinson’s
Having acute kidney injury increases the risk of developing dementia, including Parkinson’s disease with dementia, according to a study…
Gain readies for Phase 1b trial of Parkinson’s therapy GT-02287
GT-02287, an oral small molecule from Gain Therapeutics, was found to be safe and well tolerated in healthy volunteers.
Event aims to empower patients, celebrate End Parkinson’s Act
This fall, the Tampa Jewish Community Centers (JCCs) and Federation will host a symposium that aims to empower people…
Low-dose carbon monoxide may protect neurons, much like smoking
Carbon monoxide (CO), a gas present in cigarette smoke, given at low dose may help to prevent Parkinson’s disease…